IL7 and neoplasm: Despite the above common interleukin, a number of other interleukins are armed into OVs to improve antitumor activity, such as IL-7,220 IL-36γ, 233 IL-21,234 IL-24,235 and IL-18.236 The promising results will advance the clinical applications of IL-armed OVs for tumor treatment as research proceeds.